Evaxion to Present AI-Driven Polio Vaccine Concepts in Collaboration with Gates Foundation

Key Facts

1Evaxion developed novel polio vaccine concepts using its AI-Immunology™ platform.

2The concepts were developed in collaboration with the Bill & Melinda Gates Foundation.

3The research will be presented at the World Vaccine Congress in Washington D.C. (March 31 - April 2, 2026).

Evaxion A/S (NASDAQ: EVAX) has announced the development of novel polio vaccine concepts utilizing its proprietary AI-Immunology™ platform. The project was conducted in collaboration with the Bill & Melinda Gates Foundation, highlighting a significant partnership in global health innovation. The company is scheduled to present its research findings at the World Vaccine Congress in Washington D.C., taking place from March 31 to April 2, 2026. This presentation aims to demonstrate the efficacy of AI-driven design in addressing complex global health challenges and creating superior vaccine candidates. The validation provided by the Gates Foundation partnership represents a key milestone for Evaxion’s technological approach. Market analysts view this development as a positive indicator for the company's biotech platform and its future growth potential within the NASDAQ-listed biotech sector.